Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
Pharmacokinetics of pyrazinamide and its major metabolite, pyrazinoic acid, were assessed in 10 chronic uremic patients treated by maintenance hemodialysis in comparison with 10 normal subjects. All subjects ingested a single dose of 1 g of pyrazinamide, the patients receiving the drug immediately after the end of a dialysis session. Bioavailability of pyrazinamide was only slightly increased in patients, its dialysis extraction coefficient being 55.3%. In contrast, pyrazinoic acid has an elimination rate-dependent metabolism with a bioavailability markedly increased in patients and a dialysis extraction coefficient of 59.8%. These data may lead to recommendations of a reduction in the dosage of pyrazinamide in dialysis patients. However, administering the usual dosage of the drug at the end of each dialysis session seems preferable to the daily administration of a reduced dosage.
Stamatakis
G
G
Nephrology Service, Hôpital Bichat, Paris, France.
Montes
C
C
Trouvin
J H
JH
Farinotti
R
R
Fessi
H
H
Kenouch
S
S
Méry
J P
JP
D000328:Adult; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*; D014511:Uremia / Q000628:therapy
D011718:Pyrazinamide; C005296:pyrazinoic acid